Skip to main content
SpringerLink
Log in

Im Fokus — das Nierenzellkarzinom

Immunonkologische Strategien

  • journal club
  • Published:
Info Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2

Literatur

  1. Brauch H et al. World J Urol. 1994;12(3):162–8.

    Article  CAS  PubMed  Google Scholar 

  2. Kruck S et al. Expert Rev Anticancer Ther. 2012;12(6):777–85.

    Article  CAS  PubMed  Google Scholar 

  3. Ljungberg B et al. Eur Urol. 2010;58(3):398–406.

    Article  PubMed  Google Scholar 

  4. Drobyski WR, Qazi R. Am J Hematol. 1989;31(2):138–41.

    Article  CAS  PubMed  Google Scholar 

  5. Kavoussi LR et al. J Urol. 1986;135(5):1005–7.

    CAS  PubMed  Google Scholar 

  6. Bedke J et al. World J Urol. 2014;32(1):31–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Bockorny B, Dasanu CA. Expert Opin Biol Ther. 2013;13(6):911–25.

    Article  CAS  PubMed  Google Scholar 

  8. Hanahan D, Weinberg RA. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  9. Bedke J et al. Expert Rev Anticancer Ther. 2012;12(12):1503–5.

    Article  CAS  PubMed  Google Scholar 

  10. Dong H et al. Nat Med. 2002;8(8):793–800.

    CAS  PubMed  Google Scholar 

  11. Curiel TJ et al. Nat Med. 2003;9(5):562–7.

    Article  CAS  PubMed  Google Scholar 

  12. Wang QJ et al. Cancer Res. 2012;72(23):6119–29.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Hodi FS et al. N Engl J Med. 2010;363(8):711–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Yang JC et al. J Immunother. 2007;30(8):825–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Topalian SL et al. N Engl J Med. 2012;366(26):2443–54

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Brahmer JR et al. N Engl J Med. 2012;366(26):2455–65.

    Article  Google Scholar 

  17. Yang JC et al. J Clin Oncol. 2003;21(16):3127–32.

    Article  Google Scholar 

Originalie

  • Drake CG et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treatedmetastatic renal cell carcinoma (mRCC): Long-term patient follow-up. J Clin Oncol. 2013;31(Suppl): Abstr 4514.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Universität Tübingen, Tübingen, Deutschland

    Jens Bedke

  2. Klinik für Urologie, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Deutschland

    Peter J. Goebell

Authors
  1. Jens Bedke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Goebell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens Bedke.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bedke, J., Goebell, P.J. Im Fokus — das Nierenzellkarzinom. Info Onkol. 17, 23–26 (2014). https://doi.org/10.1007/s15004-014-0840-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-014-0840-z

Schlüsselwörter

Search

Navigation